Med. Pro Praxi 2007; 3: 102-104

Nízkomolekulární hepariny v ambulantní praxi při léčbě hluboké žilní trombózy

doc. MUDr. Věra Krčová CSc
Hemato-onkologická klinika FN a LF UP v Olomouci

Hluboká žilní trombóza (HŽT) a plicní embolie (PE), tedy žilní tromboembolická nemoc (TEN) je poměrně časté, život ohrožující onemocnění. V akutní fázi jsou nemocní ohroženi rozvojem PE. V dalším období může dát vznik zejména chronické žilní insuficienci a recidivám žilní trombózy. Základním lékem v léčbě HŽT je heparin. Cílem léčby HŽT heparinem je zabránit extenzi trombu, předejít vzniku a rozvoji PE a v budoucnu recidivě HŽT nebo vzniku posttrombotického syndromu. V České republice se udává výskyt HŽT asi ve 20 000 případů ročně, z nich končí 1–2 % smrtelnou PE a 20–50 % chronickým posttrombotickým syndromem s různým stupněm závažnosti.

Keywords: tromboembolická nemoc, nízkomolekulární hepariny, ambulantní léčba

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krčová V. Nízkomolekulární hepariny v ambulantní praxi při léčbě hluboké žilní trombózy. Med. praxi. 2007;4(3):102-104.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Büller HR, Agnelli G, Hull RD, et al. Antitrombotic therapy for venous Thromboembolic disease. The seventh ACCP Conference on Antithrombotic and Fibrinolytic Therapy. Chest 2004; 126: 4015-4285. Go to original source... Go to PubMed...
    2. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism the seventh ACCP Conference on antithrombotic therapy chest. 2004; 126: 338S-400S.
    3. Ginsberg JS, Hirsh J. Treatment of venous thromboembolism. from hemostasis and thrombosis, Lippincott William and Wilkins, 2001: 1405-1413.
    4. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin. Circulation 2001; 103: 2994-3018. Go to original source...
    5. Hirsh J. Low-molecular weight heparin for the treatment of venous thromboembolism. Am. Heart J. 1998; 135: S 336-342. Go to original source... Go to PubMed...
    6. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982. Go to original source... Go to PubMed...
    7. Hyers (TM). Management of venous thromboembolism Arch Intern Med 2003; 163: 759-768. Go to original source... Go to PubMed...
    8. Karetová D. Antikoagulační léčba flebotrombóz v ambulantní praxi. Vnitřní Lék. 2005; 51: 790-794.
    9. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractioned heparin administered in the hospital compared with subcutaneous low-molecularweight heparin administered at home. New Engl J Med 1996, 334: 682-687. Go to original source... Go to PubMed...
    10. Kovacs MJ, Anderson D, Morrow B, et al. Outpatient treatment of pulmonary embolism with dalteparin. Tromb Haemost 2000; 83: 209-211. Go to original source...
    11. Lapidus L, Borretzen J, Fahlén M, Thomsen HG, Hasselblom S, Larson L, Nordstrom H, Stigendal L, Walter L. Home treatment of deep vein trombosis. An out-patient treatment model with one daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Patophysiol. Haemost. Tromb. 2002; 32, 2: 59-66. Go to original source... Go to PubMed...
    12. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered pimaxily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl Med 1996, 334: 677-681. Go to original source... Go to PubMed...
    13. Partsch H. Bed rest versus ambulation in the initial treatment of patiens with proximal deep vein thrombosis. Curr Opin Pulm Med. 2002 Sep; 8 (5): 389-393. Go to original source... Go to PubMed...
    14. Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of produmal deep venous trombosis with low molecular weight heparin. J. BASF. Surg. 2000; 32: 861-869. Go to original source...
    15. Turpie AG. Choise of low molecular weight heparins. J Thromb Haemost. 203; 1:598.
    16. Weitz JI. Low-molecular-weight heparins, N Engl J Med 1997, 337: 688-698. Go to original source... Go to PubMed...
    17. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119: 95S-107S. Go to original source... Go to PubMed...
    18. Widimský J, Malý J, a kolektiv. Akutní plicní embolie a žilní trombóza, Nakl. Tritin 2005: 381 s.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.